Scientists test genetically weakened parasite as a malaria vaccine
NCT ID NCT06862453
Summary
This is the first human study of a new malaria vaccine called PfSPZ-LARC2. It uses a live but genetically weakened malaria parasite that is designed to stop developing in the liver, preventing a full-blown infection. The main goals are to see if the vaccine is safe and tolerable in 58 healthy adults who have never had malaria, and to test how well it protects them against a controlled malaria challenge.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA,FALCIPARUM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Tubingen
Wilhelmstraße 27, Tubingen, 72074, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.